Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2025)

Historic Research & Development for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $23.3 million.

  • Arcturus Therapeutics Holdings' Research & Development fell 4055.04% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.5 million, marking a year-over-year decrease of 3004.27%. This contributed to the annual value of $195.2 million for FY2024, which is 157.34% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Research & Development stood at $23.3 million, which was down 4055.04% from $29.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Research & Development high stood at $58.7 million for Q2 2024, and its period low was $23.3 million during Q3 2025.
  • Moreover, its 5-year median value for Research & Development was $43.8 million (2024), whereas its average is $41.9 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 53218.39% in 2021, then crashed by 4958.33% in 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Research & Development (Quarter) stood at $32.6 million in 2021, then dropped by 17.32% to $27.0 million in 2022, then surged by 35.73% to $36.6 million in 2023, then increased by 19.55% to $43.8 million in 2024, then tumbled by 46.86% to $23.3 million in 2025.
  • Its Research & Development was $23.3 million in Q3 2025, compared to $29.6 million in Q2 2025 and $34.9 million in Q1 2025.